Energy-level alignment at model interfaces of organic electroluminescent devices studied by UV photoemission: trend in the deviation from the traditional way of estimating the interfacial electronic structures

The electronic structures of model interfaces of organic electroluminescent (EL) devices were investigated with UV photoemission spectroscopy (UPS). Interfaces of TTN (tetrathianaphthacene) and TCNQ (tetracyanoquinodimethane) were also studied as extreme cases for hole transport and electron transport material, respectively. For all organic/metal interfaces studied, the work function of metal electrode was changed by deposition of organic layer, i.e., the vacuum level was shifted at the interface, indicating the invalidity of the traditional energy level alignment model where a common vacuum level was assumed at organic/metal interface. At TCNQ/Au, DP-NTCI/Al, which are acceptor/metal interfaces, upward shift of the vacuum level of organic layer relative to that of metal was observed, suggesting the formation of interfacial dipole due to electron-transfer from metal to acceptor. At other organic/metal interfaces, TPD(N, N'-diphenyl-N, N'-(3-methylphenyl)-1, 1'-biphenyl-4, 4'-diamine)/Au or ITO (indium tin oxide), ALq/sub 3/ (tris(8-hydroxyquinolino) aluminum)/Al, DP-NTCl(N, N'-diphenyl-1,4,5,8- naphthyltetracarboxylimide)/Al or Au, downward shift of the vacuum level was observed. Such downward shift has been also observed in our previous study for porphyrin/metal interfaces, and seems to be a trend for organic/metal interfaces at which no electron-transfer from metal to organic layer occurs. This trend suggests that the traditional model tends to underestimate (overestimate) the barrier height for hole (electron) injection. On the other hand, the vacuum level shift at ALq/sub 3//TPD interface was less than 0.1 eV, leading to an apparent applicability of the traditional model. However, it is not always the case for organic/organic interfaces: finite shift of 0.2 eV was observed at TTN/TCNQ interface due to electron-transfer from TTN to TCNQ. Possible origins of vacuum level shift at organic/metal interfaces were also discussed.     

Methanol decomposition to synthesis gas over supported Pd catalysts prepared from synthetic anionic clays

Supported Pd or Rh catalysts were prepared by the solid-phase crystallization method starting from hydrotalcite anionic clay minerals based on [Mg₆Al₂(OH)₁₆CO ₂ ²⁻ ]·4H₂O as the precursors. The precursors were prepared by a coprecipitation method from the raw materials containing Pd²⁺ and various trivalent metal ions which can replace each site of Mg²⁺ and Al³⁺ in the hydrotalcite. Rh³⁺ was also used for preparing the catalyst as comparison. The precursors were then thermally decomposed and reduced to form supported Pd or Rh catalysts and used for the methanol decomposition to synthesis gas. Among the precursors tested, use of Mg–Cr hydrotalcite containing Pd²⁺ resulted in the formation of efficient Pd supported catalysts for the production of synthesis gas by selective decomposition of methanol at low temperature. Although Pd²⁺ cannot well replace the Mg²⁺ site in the hydrotalcite, the Pd supported catalyst (Pd/Mg–Cr) prepared by the solid-phase crystallization method formed highly dispersed Pd metal particles and showed much higher activity than that prepared by the conventional impregnation method. When the precursor was prepared under mild conditions, more fine particles of Pd metal were formed over the catalyst, resulting in high activity. It is likely that the high activity may be due to the highly dispersed and stable Pd metal particles assisted by the role of Cr as the co-catalyst. This revised version was published online in November 2006 with corrections to the Cover Date.     

Depression during interferon therapy in chronic hepatitis C patients--a prospective study

The number of patients treated with interferon (IFN) has increased markedly in Japan since 1992, when the Health and Welfare Ministry approved the use of IFN for treating chronic active hepatitis C. It is important to identify and treat depression, which is one of the psychiatric complications of IFN therapy and often leads to discontinuation of the therapy, in patients with chronic hepatitis C. In this study we prospectively investigated the incidence of depression during IFN therapy in patients with chronic active hepatitis C. The psychiatric status of 85 patients (53 men, 32 women; mean age 49.1 years) with chronic active hepatitis C who began receiving IFN at Showa University Hospital was assessed before and 2, 4, 12 and 24 weeks after the start of IFN therapy, using the major depressive episode diagnostic criteria listed in the DSM-III-R and the Hamilton Depression Scale HDS). All of the patients provided informed consent prior to participation in this study. IFN therapy was discontinued in 5 cases (5.9%) because of physical side effects and in 4 cases (4.7%) because of depression. Two, 11, 14, 25 and 16 patients were diagnosed as having major depressive episodes before and 2, 4, 12 and 24 weeks after the start of IFN therapy, respectively. The number of patients who were asymptomatic before the start of IFN therapy but were diagnosed as having a major depressive episode at least once during IFN therapy was 31 (31/83 = 37.3%). The mean HDS scores at 2, 4, 12 and 24 weeks (5.4, 6.0, 8.8 and 6.6) were significantly higher than that before the start of IFN therapy (3.0). The patients whose first diagnosed major depressive episodes occurred more than 4 weeks after the start of IFN therapy tended to be more severely depressed than those in whom it occurred less than 4 weeks after the start of IFN therapy. Compared to the 47 patients who completed 24 weeks of IFN therapy without experiencing depression, the 31 patients who were diagnosed as experiencing major depressive episodes during IFN therapy had significantly higher neuroticism scores determined using the Eysenck Personality Questionnaire, showed a more severely depressed mood and experienced more severe sleep disturbances before the start of IFN therapy. The latter group of patients also tended to have comorbid chronic physical disorders such as hypertension or diabetes mellitus and the histories of mental disorders before the IFN therapy; however these differences were not statistically significant. There were no differences between the two groups in patient age or sex, the severity of hepatitis before the IFN therapy, the type of IFN used in the therapy or the efficacy of IFN in the treatment of the hepatitis C. Our results indicate that the decision as to whether to treat chronic active hepatitis C with IFN should be made carefully and that early intervention and careful monitoring of depression are required during IFN therapy in the treatment of chronic active hepatitis C.     

A 39-to-45-Gbit/s multi-data-rate clock and data recovery circuit with a robust lock detector

We describe a 40-Gbit/s-class clock and data recovery (CDR) circuit with an extremely wide pull-in range. A Darlington-type voltage-controlled oscillator (VCO) is newly designed to cover the STM-256/OC-768 full-rate-clock frequencies with a wide frequency margin. We also describe a new lock detector using an exclusive-NOR gate. The CDR IC was fabricated using InP/InGaAs HBTs. Error-free operation and wide eye opening were confirmed for 40-, 43-, and 45-Gbit/s PRBS with a word length of 2/sup 31/ - 1. We attached a frequency search and phase control (FSPC) circuit to the chip as a new frequency acquisition aid, and this allows the CDR circuit to pull in throughout a 39-45-Gbit/s range. The peak-to-peak and rms jitter of the recovered clock were 3.6 and 0.48 ps, respectively.     

Semiconductor pump laser technology

Recent progress in high-power semiconductor lasers for erbium-doped fiber amplifiers is described, focusing on 1.48-μm InGaAsP/InP lasers and 0.98-μm InGaAs/GaAs lasers. The experimental output powers exceed 200 mW (the maximum power was 325 mW) for 1.48-μm lasers, and simulation results indicate that over 400 mW could be obtained by optimizing parameters in strained-layer (SL) multiple-quantum-well (MQW) lasers. Stable operation over a few thousand hours under 100-mW power is demonstrated for liquid-phase-epitaxy-grown lasers, MQW lasers, and SL-MQW lasers grown by all-metal organic vapor-phase epitaxy (MOVPE). For 0.98-μm lasers, improvement in the fiber coupling efficiencies and long-term reliabilities are described. Their power coupled into a single-mode fiber has reached over 100 mW, with coupling efficiencies of approximately 40%. Although reliability seems to be one of the drawbacks compared with 1.48-μm lasers, stable operation for over 10,000 h at 50°C and 30 mW has been reported     

Successful engraftment of unrelated cord blood stem cells for familial erythrophagocytic lymphohistiocytosis. Kinki Cord Blood Bank

PURPOSE: To describe a case of Felty syndrome (FS) in a child with (JRA) and review the previous literature on this rare entity. METHODS: Review of clinical data including results of serial blood counts, bone marrow aspirate, human leukocyte antigen (HLA)-typing, and abdominal sonography. RESULTS: Serial blood counts over 2 years revealed persistent leukopenia and thrombocytopenia. Bone marrow aspirate showed normal trilineage hematopoiesis, abdominal sonography demonstrated an enlarged spleen, but normal liver and portal circulation. HLA-typing was most significant for positivity of the DR 1 allele. CONCLUSION: This is only the third child, and the first preadolescent, to be reported with FS complicating juvenile rheumatoid arthritis. This condition needs to be considered in the differential diagnosis when leukopenia, thrombocytopenia, or both develop in patients with JRA.